Plain-English translation of NCT05431764 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach for people with newly diagnosed nasopharyngeal cancer that has spread to other parts of the body. The treatment combines three things: chemotherapy (gemcitabine and cisplatin), an immunotherapy drug called camrelizumab, and targeted radiation aimed at both the original tumor and the spread sites. The goal is to see if treating all the cancer sites together — rather than just the original tumor — gives better results.
Nasopharyngeal cancer that has already spread when diagnosed is hard to treat, and standard chemotherapy and immunotherapy alone don't always control the disease well enough. This trial is exploring whether adding very focused radiation treatment to hit all the cancer spots — combined with ongoing immunotherapy — could improve survival and keep the cancer under control longer.
You would receive six cycles of chemotherapy combined with the immunotherapy medication over several months. After that, you would receive focused radiation treatments aimed at both your original tumor and the spots where cancer has spread. Following radiation, you would continue taking the immunotherapy medication as maintenance therapy. Throughout the trial, you would have regular imaging scans (MRI and PET-CT) and blood tests to monitor how well the treatment is working and check for any side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China